# A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Source: https://onco.cc/trials/nct06335355/  
OnCo record `nct06335355` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of adebrelimab, SHR-8068, pemetrexed, carboplatin and other drugs in lung cancer, run by Shanghai Shengdi Pharmaceutical Co., Ltd, not yet recruiting.

## Summary

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients is a phase 2/3, randomised interventional study registered as NCT06335355 by Shanghai Shengdi Pharmaceutical Co., Ltd, with a registry enrolment figure of 401 participants, started 2024-03 and due to reach its primary completion in 2028-10. Interventions recorded: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin; Camrelizumab + Pemetrexed + Carboplatin; Adebrelimab + Pemetrexed + Carboplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. Primary outcome: Investigator-assessed Objective Response Rate (Phase One); Overall Survival (Phase Two). Lung eligibility wording from the registry: "Diagnosed with advanced or metastatic non-squamous NSCLC (non-small cell lung cancer) confirmed by histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06335355
- Phase: 2/3
- Setting: A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations
- Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
- Enrolled: 401

## Sources

- ClinicalTrials.gov NCT06335355: https://clinicaltrials.gov/study/NCT06335355

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [SHR-8068](https://onco.cc/drugs/shr-8068/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06335355.json